SCHEMBL1493216

SCHEMBL1493216

O=C(O)CNC(=O)CNC(=O)CS

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
MAPT P10636 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
LMNA P02545 1/20 0.41
PTGS2 P35354 1/20 0.41
MME P08473 5/20 0.39
EGLN1 Q9GZT9 2/20 0.38
ITGB1 P05556 1/20 0.37
ITGA5 P08648 1/20 0.37
FAAH O00519 5/20 0.36
ACE P12821 2/20 0.35
CPA1 P15085 1/20 0.35
ACE2 Q9BYF1 1/20 0.35
PTPN1 P18031 1/20 0.35
CTH P32929 1/20 0.34
HPGD P15428 2/20 0.34
HSD17B10 Q99714 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
USP2 O75604 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14417106 1.00 ALDH1A1 (0.41) ALDH1A1MAPTTDP1LMNAPTGS2
Mertiatide SCHEMBL136462 1.00 ALDH1A1 (0.41) ALDH1A1MAPTTDP1LMNAPTGS2
Mertiatide SCHEMBL23522195 0.98 ALDH1A1 (0.40) ALDH1A1MAPTTDP1LMNAPTGS2
SCHEMBL2796838 0.98 ALDH1A1 (0.40) ALDH1A1MAPTTDP1LMNAPTGS2
Mertiatide SCHEMBL1650428 0.95 ALDH1A1 (0.39) ALDH1A1MAPTTDP1LMNAPTGS2
SCHEMBL75812 0.95
SCHEMBL12762758 0.88 ALDH1A1 (0.34) ALDH1A1MAPTTDP1LMNAPTGS2
Glycine SCHEMBL4653213 0.86 GLRA1 (0.46) ALDH1A1MAPTTDP1LMNAPTGS2
Glycine SCHEMBL4264488 0.86 GLRA1 (0.46) ALDH1A1MAPTTDP1LMNAPTGS2
SCHEMBL610938 0.84 ALDH1A1 (0.38) ALDH1A1MAPTTDP1LMNAPTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260048156-A1 FAP-TARGETING PHARMACEUTICAL PRODUCT FOR THERAPY AND DIAGNOSIS OF CANCERS Atoms for Cure GmbH (DE) 2026-02-19 US claimed
US-20250235566-A1 TRISLINKER-CONJUGATED DIMERIC LABELING PRECURSORS AND RADIOTRACERS DERIVED THEREFROM Medianezia GmbH (DE) 2025-07-24 US claimed
WO-2025125621-A1 CANCER-ASSOCIATED PROTEIN-TARGETED STRONG OR COVALENTLY BINDING PRECURSOR COMPOUNDS AND RADIOTRACERS RADIOVAXX GMBH (DE) 2025-06-19 WO claimed
EP-4486395-A1 PRECURSOR MARKERS AND RADIOTRACERS WITH THREE OR MORE TARGETING VECTORS FOR THERANOSTICS USED IN NUCLEAR MEDICINE Atoms for Cure GmbH (DE) 2025-01-08 EP claimed
EP-4452326-A1 FAP-TARGETING PHARMACEUTICAL PRODUCT FOR THERAPY AND DIAGNOSIS OF CANCERS Atoms for Cure GmbH (DE) 2024-10-30 EP claimed
EP-4351663-A1 TRISLINKER-CONJUGATED DIMERIC LABELLING PRECURSORS AND RADIOTRACERS DERIVED THEREFROM Medianezia GmbH (DE) 2024-04-17 EP claimed
WO-2023165987-A1 PRECURSOR MARKERS AND RADIOTRACERS WITH THREE OR MORE TARGETING VECTORS FOR THERANOSTICS USED IN NUCLEAR MEDICINE Atoms for Cure GmbH (DE) 2023-09-07 WO claimed
CN-116710150-A Radiolabelled ether dendrimer conjugates for PET imaging and radiation therapy 阿什瓦塔治疗股份有限公司 2023-09-05 CN claimed
CN-116635408-A Reactive conjugates 德彪药业国际股份公司 2023-08-22 CN claimed
WO-2023118195-A1 FAP-TARGETING PHARMACEUTICAL PRODUCT FOR THERAPY AND DIAGNOSIS OF CANCERS Atoms for Cure GmbH (DE) 2023-06-29 WO claimed
WO-2022258637-A1 TRISLINKER-CONJUGATED DIMERIC LABELLING PRECURSORS AND RADIOTRACERS DERIVED THEREFROM Atoms for Cure GmbH (DE) 2022-12-15 WO claimed
US-8575100-B2 Tc and Re labeled radioactive glycosylated octreotide derivatives MALLINCKRODT LLC (US) 2013-11-05 US claimed
US-7589061-B2 Tc and Re labeler radioactive glycosylated octreotide derivatives MALLINCKRODT INC. (US) 2009-09-15 US claimed
US-20060189567-A1 Compound having affinity with calcified tissue NIHON MEDI-PHYSICS CO., LTD. (JP) 2006-08-24 US claimed
EP-1609797-A1 COMPOUND HAVING AFFINITY WITH CALCIFIED TISSUE Nihon Medi-Physics Co., Ltd. (JP) 2005-12-28 EP claimed
US-20260048156-A1 FAP-TARGETING PHARMACEUTICAL PRODUCT FOR THERAPY AND DIAGNOSIS OF CANCERS Atoms for Cure GmbH (DE) 2026-02-19 US disclosed
US-20250235566-A1 TRISLINKER-CONJUGATED DIMERIC LABELING PRECURSORS AND RADIOTRACERS DERIVED THEREFROM Medianezia GmbH (DE) 2025-07-24 US disclosed
EP-0570493-A1 TECHNETIUM-99m LABELED POLYPEPTIDES FOR IMAGING Diatide, Inc. (US) 1993-11-24 EP disclosed
US-5225180-A Technetium-99m labeled somatostatin-derived peptides for imaging DIATECH, INC. (US) 1993-07-06 US disclosed
WO-1992013572-A1 TECHNETIUM-99m LABELED POLYPEPTIDES FOR IMAGING DIATECH, INC. (US) 1992-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048156-A1 FAP-TARGETING PHARMACEUTICAL PRODUCT FOR THERAPY AND DIAGNOSIS OF CANCERS FAP, ALK, FIBP ALDH1A1 1160/4885MAPT 3883/4885TDP1 1760/4885
US-20250235566-A1 TRISLINKER-CONJUGATED DIMERIC LABELING PRECURSORS AND RADIOTRACERS DERIVED THEREFROM TK1, TK2, TMT1A ALDH1A1 2879/4885MAPT 2314/4885TDP1 1689/4885
US-20060189567-A1 Compound having affinity with calcified tissue SLC7A1, MBNL1, SHBG ALDH1A1 959/4885MAPT 3803/4885TDP1 4878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.